Bourbon, Jon, first thanks for the first hand intelligence for the front lines.
While it may have seemed like CM was slow rolling the M/S topic, IMHO that there is more going on than meets the eye. My personal assessment is that there is still a valid possibility for a partnership but that at this stage Biogen has not raised the the financial options to a level that is attractive to Anavex. And, CM knows that will change with the pending success of any of the upcoming trials.
Pertinent points:
- 2-73 has been in the premier commercial M/S lab for a year and a half under the current MTA. It is well beyond petri dish stage!
- A successful "in vivo" study by Dr Lasik at WSU showing the positive indication of remyelination properties of 2-73
- The poor "Synergy" trial results of Opicinumab, Biogen's remyelination drug candidate
- The pressure of competitors on Biogen's M/S drug line up. Biogen derives more than 70% of its revenue from M/S. Current sp has been driven down to the mid $200s.
- Biogen chief scientists own statements (Biogen Lab Video) that remyelination is the future of M/S treatment
So, while M/S is not on Anavex limited front burners, it highly likely still on the boil on the back burners.
Previous DD:
----------
McM, The MTA for M/S seems to be discussed ad infinitum. The Sep 2016 PR announcing the MTA said this : " A satisfactory result from the OPC assay may lead to an in vivo remyelination study using a chemical demyelination model." Given that the MTA is still in progress and your info on the average length for an in vivo study, the testing and data analysis must be in the final stage or complete. Also given that the Biogen Laboratory would be considered one if not the most advanced facility for the testing of M/S drugs, IMHO ANAVEX/Biogen know the potential of 2-73 as a M/S treatment. Consequently, there is high probability that we are in the business negotiation stage currently. The Wayne State presentation given the current ANAVEX/Biogen/WSU lash-up is just academic underpinning for FDA submission.
From my previous post on the subject with the Biogen Lab video which points out the importance of REMYELINATION to the treatment of M/S.
Talon
-----
Re: TTTav66 post# 122777
Post # of 124936
TT, Great deep dive into due diligence, especially about Biogen's collaboration with WSU. I have mentioned in previous posts that the request for the MTA was probably initiated by Biogen based on problems with Opicinumab (Anti-Lingo), their primary remyelination drug and their knowledge of 2-73's remyelination success in the WSU study. This may add credence to that point. The upcoming presentation by WSU will also add to validation of the efficacy of the Sigma 1 platform in M/S. How much this was abetted by the in-house testing by Biogen's lab may soon be known.
The evidence that 2-73 may play a role in Biogen's core M/S program is mounting. At the risk being redundant, I will relink the Biogen Lab video, where Dr Sandrock and three other Drs expound on the crucial importance of remyelination to effective M/S treatment.
And another Biogen fact, Camille Lee has just been hired as SVP for Alzheimer's Therapeutic Area and will report to Dr. Sandrock, Biogen's Chief Medical Officer,. The plot thickens!
Market Data 
Markets 
AI
